- DARTISLA ODT is available as a 1.7 mg orally disintegrating tablet and is indicated for adults to reduce symptoms of a peptic ulcer as an adjunct to treatment of peptic ulcer - First and only orally ...
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and ...
A recently filed patent (Publication Number: US20230263735A1) describes a film-coated tablet with specific compositions and properties. The tablet consists of a core tablet coated with two film layers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback